Price Discrimination for Pharmaceuticals: Welfare Effects in the US and the EU
暂无分享,去创建一个
[1] Ramsey pricing and competition: The consequences of myopic regulation , 1996 .
[2] David L. Bradford,et al. Optimal Departures from Marginal Cost Pricing , 1970 .
[3] D. Dranove,et al. Pricing by non-profit institutions. The case of hospital cost-shifting. , 1988, Journal of health economics.
[4] P. Danzon. Trade and Price Differentials for Pharmaceuticals: Policy Options , 1997 .
[5] L Lasagna,et al. Cost of innovation in the pharmaceutical industry. , 1991, Journal of health economics.
[6] F. Ramsey. A Contribution to the Theory of Taxation , 1927 .
[7] Richard E. Caves,et al. Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry , 1991 .
[8] J. Laffont,et al. A Theory of Incentives in Procurement and Regulation , 1993 .
[9] R. R. Braeutigam. Socially Optimal Pricing with Rivalry and Economies of Scale , 1984 .
[10] C. Rochlin,et al. ADVERTISING AS A PRIVATELY SUPPLIED PUBLIC GOOD , 1979 .
[11] Parallel Trade in Pharmaceuticals: The Impact on Welfare and Innovation , 1992 .
[12] Ian Cockburn,et al. Racing or spilling? : the determinants of research productivity in ethical drug discovery , 1996 .
[13] Frederic M. Scherer,et al. How US Antitrust Can Go Astray: The Brand Name Prescription Drug Litigation , 1997 .
[14] Henry G. Grabowski,et al. Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act , 1992, The Journal of Law and Economics.